Heiman Wertheim (07-12-1970) is a professor in clinical microbiology and heads the clinical microbiology department at Radboud University Medical Center and is chair of the Radboud Center of Infectious Diseases (RCI, www.radboudrci.nl). RCI unites all efforts at Radboudumc to tackle infectious diseases, from fundamental work to clinical trials to population based studies. Heiman operates in an international network spanning Asia and Africa where he conducts his research, partly through his position at the University of Oxford. Until 2015, Heiman was director of the Oxford University Clinical Research Unit (OUCRU, www.oucru.org) in Hanoi, Vietnam. He works with a multidisciplinary approach to have an impact on global healthcare, particularly in the area of antimicrobial resistance spanning: health systems, policy development, behaviour, surveillance, prevention, genomics, and clinical trials. Heiman is currently part of a WHO expert panel looking at mass drug administration of azithromycin to reduce mortality in infants. He is on the advisory board of RIVM/Cib (national Center for Infectious Disease Control) and executive board of the Netherlands Center for One Health (NCOH). Heiman is board member for the Netherlands Society Medical Microbiology. He has over 190 publications and a google scholar H-index of 51.